INCREASED VASCULAR SELECTIVITY AND PROLONGED PHARMACOLOGICAL EFFICACY OF THE L-TYPE Ca super(2+) CHANNEL ANTAGONIST LERCANIDIPINE IN HUMAN CARDIOVASCULAR TISSUE

1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental pharmacology & physiology Vol. 32; no. 9; pp. 708 - 713
Main Authors Brixius, Klara, Gross, Thomas, Tossios, Paschalios, Geissler, Hans-Joachim, Mehlhorn, Uwe, Schwinger, Robert Hg, Hekmat, Khosro
Format Journal Article
LanguageEnglish
Published 01.09.2005
Online AccessGet full text

Cover

Loading…
Abstract 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic heart transplants) or in isolated right atrial trabeculae and isolated vessel preparations of arteria mammaria obtained from patients undergoing aortocoronary bypass operation. 2. The obtained rank order for the L-type Ca super(2+) channel affinity in human tissue was LER > NIF greater than or equal to AML. Lercanidipine had the lowest negative inotropic efficacy (1 mu mol-L LER: 60.3% basal < AML: 79.1% basal < NIF: 92.4 basal) and potency (IC sub(50) NIF: 3.5 nmol-L < AML: 48 nmol-L < Ler: 127 nmol-L) in right atrial trabeculae. 3. The vasorelaxant potency of LER (IC sub(50) 0.5 nmol-L) and AML (IC sub(50) 0.8 nmol-L) was similar and significantly increased compared with that of NIF (IC sub(50) 5.9 nmol-L) in arteria mammaria preparations of the very same patients. 4. The following rank order was obtained for vasoselectivity: LER (260) < AML (60) < NIF (0.6). 5. The pharmacological effects of LER and AML were still present 2 h after drug washout. 3. Lercanidipine is characterized by a high vasoselectivity and a prolonged interaction with the L-type calcium channel in human cardiovascular tissue This may be advantageous, especially in the treatment of patients with arterial hypertension.
AbstractList 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic heart transplants) or in isolated right atrial trabeculae and isolated vessel preparations of arteria mammaria obtained from patients undergoing aortocoronary bypass operation. 2. The obtained rank order for the L-type Ca super(2+) channel affinity in human tissue was LER > NIF greater than or equal to AML. Lercanidipine had the lowest negative inotropic efficacy (1 mu mol-L LER: 60.3% basal < AML: 79.1% basal < NIF: 92.4 basal) and potency (IC sub(50) NIF: 3.5 nmol-L < AML: 48 nmol-L < Ler: 127 nmol-L) in right atrial trabeculae. 3. The vasorelaxant potency of LER (IC sub(50) 0.5 nmol-L) and AML (IC sub(50) 0.8 nmol-L) was similar and significantly increased compared with that of NIF (IC sub(50) 5.9 nmol-L) in arteria mammaria preparations of the very same patients. 4. The following rank order was obtained for vasoselectivity: LER (260) < AML (60) < NIF (0.6). 5. The pharmacological effects of LER and AML were still present 2 h after drug washout. 3. Lercanidipine is characterized by a high vasoselectivity and a prolonged interaction with the L-type calcium channel in human cardiovascular tissue This may be advantageous, especially in the treatment of patients with arterial hypertension.
Author Geissler, Hans-Joachim
Tossios, Paschalios
Brixius, Klara
Schwinger, Robert Hg
Hekmat, Khosro
Mehlhorn, Uwe
Gross, Thomas
Author_xml – sequence: 1
  givenname: Klara
  surname: Brixius
  fullname: Brixius, Klara
– sequence: 2
  givenname: Thomas
  surname: Gross
  fullname: Gross, Thomas
– sequence: 3
  givenname: Paschalios
  surname: Tossios
  fullname: Tossios, Paschalios
– sequence: 4
  givenname: Hans-Joachim
  surname: Geissler
  fullname: Geissler, Hans-Joachim
– sequence: 5
  givenname: Uwe
  surname: Mehlhorn
  fullname: Mehlhorn, Uwe
– sequence: 6
  givenname: Robert
  surname: Schwinger
  middlename: Hg
  fullname: Schwinger, Robert Hg
– sequence: 7
  givenname: Khosro
  surname: Hekmat
  fullname: Hekmat, Khosro
BookMark eNqNjt1KwzAcxYNMsFPf4X8lirQm_dp2GdK0DWRpadJBr0aRCo7azcWCj-OjmgvZtefmcDg_DmeJFtNxGhACggPi9HIISBxjn6RrEoQYJwGOwzQJvq-QdykWyMMRTnyyXuEbtLT2gB2J08hDP0KxhlPNM9hRzVpJG9BccmbETpgOqMqgbipZqcIhdUmbLWUuFoJRCTzPnbMOqhxMyUH6pqs5sB7sfBrOj-HzE7CSKsWlWzK0qJTQBiRvGFUiE7VQHISCst1SBYw2maguN4zQuuV36PqtH-1w_-e36CHnhpX-6Xz8nAf7tf94t6_DOPbTcJztnqziaJMmm-jf4C-TFlph
ContentType Journal Article
DBID 7QP
DOI 10.1111/j.1440-1681.2005.04265.x
DatabaseName Calcium & Calcified Tissue Abstracts
DatabaseTitle Calcium & Calcified Tissue Abstracts
DatabaseTitleList Calcium & Calcified Tissue Abstracts
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1440-1681
EndPage 713
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29B
2QV
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
7QP
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DXH
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KTM
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
ID FETCH-proquest_miscellaneous_174396593
ISSN 0305-1870
IngestDate Sat Aug 17 03:11:09 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel OpenURL
MergedId FETCHMERGED-proquest_miscellaneous_174396593
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
PQID 17439659
PQPubID 23462
ParticipantIDs proquest_miscellaneous_17439659
PublicationCentury 2000
PublicationDate 20050901
PublicationDateYYYYMMDD 2005-09-01
PublicationDate_xml – month: 09
  year: 2005
  text: 20050901
  day: 01
PublicationDecade 2000
PublicationTitle Clinical and experimental pharmacology & physiology
PublicationYear 2005
SSID ssj0005063
Score 3.537548
Snippet 1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and...
SourceID proquest
SourceType Aggregation Database
StartPage 708
Title INCREASED VASCULAR SELECTIVITY AND PROLONGED PHARMACOLOGICAL EFFICACY OF THE L-TYPE Ca super(2+) CHANNEL ANTAGONIST LERCANIDIPINE IN HUMAN CARDIOVASCULAR TISSUE
URI https://search.proquest.com/docview/17439659
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9pAEIBXNL30UrVJq747hxa1chwRjI193CwGOzW2ZS9ROCEDRuIQiAKWmv6a_rj-kI7X7zZq2l4MMtYamE-zM-N5EPJhqSsaWgW6nFqjMu5QimxoRldWjNO5vlRXnZ7ozj92NWvSO79UL1utH7WspWQ_P1l8u7Ou5H-kiudQrmmV7D9ItlwUT-B7lC8eUcJ4_CsZo0cemDQ0B9IFDdnEoYEUmo7JuH1h86noHOUHnuO5I7zEt2gwpqycfoAWKr6yaZH348h86psSi6Rdcp0KUu9-7J6lUQNmUdc1HVyP05Hn2iGXHDNg1LUHtm-76dR6yZqMqSsxGgxsr_wy3A7DiVm3f1lRiJnG6xvTBa6rHtpZEo-IuTSC_mc366_rRID3BR3yckMZFaPfa9lOInCeZvjmgwjQiUePY1t-OIqRuLwK0sLtWj5PK8vWV40oiFqmeZXVX2lHVT0bQnISZ8pcPLfWspEwhbavoqlJkc-eqe5-R69ZAf2sQvYPG0y-dh6WQ0NHLRJP6z29XW82nDjOjJuX_AF52EV1KJIJgqrJmZrP-yt-QTPf7M77_GY4CGuIPyGPczcGaMbkU9KKN4fkiG6i_fbqFtrgl8I7JG0_E-3tMfCq2m93LC6rhH5Evpc8Q4EQ1HgG5BlKnuEXnqHgGbwhIM-Q8QwsAsHzp670GXKSoSIZGiSD7YIgGZokQ0byM9IempxZcvG3zFBLpo--ok28TXYz4XdrqqE8Jweb7SZ-QWC-6MWd2FB6htrvLRdKFPcjY66tUEl1FqfR6iV5f89ir-694jV5VMH6hhzsb5L4LRqx-_k7wcBPOWGLzg
link.rule.ids 315,783,787,27936,27937
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=INCREASED+VASCULAR+SELECTIVITY+AND+PROLONGED+PHARMACOLOGICAL+EFFICACY+OF+THE+L-TYPE+Ca+super%282%2B%29+CHANNEL+ANTAGONIST+LERCANIDIPINE+IN+HUMAN+CARDIOVASCULAR+TISSUE&rft.jtitle=Clinical+and+experimental+pharmacology+%26+physiology&rft.au=Brixius%2C+Klara&rft.au=Gross%2C+Thomas&rft.au=Tossios%2C+Paschalios&rft.au=Geissler%2C+Hans-Joachim&rft.date=2005-09-01&rft.issn=0305-1870&rft.eissn=1440-1681&rft.volume=32&rft.issue=9&rft.spage=708&rft.epage=713&rft_id=info:doi/10.1111%2Fj.1440-1681.2005.04265.x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1870&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1870&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1870&client=summon